Results 151 to 160 of about 550,911 (287)

Biostatistics [PDF]

, 2020
openaire   +2 more sources

Building research capacity among health care professionals in LMICs: experiences from the 9th Tata Annual Biostatistics and Research Methods Course, 2025. [PDF]

Ecancermedicalscience
Datta SS, Ghosh J, Choudhury D, Datta SS, Jain P, Adhia S, Mallick I, Agrawal S, Garg S, Ghosh S, Nag A, Mukherjee A, Ghose S, Das S, Mukherjee R, Sarkhel S, Arun P.   +16 more
europepmc   +1 more source

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative

Clinical Pharmacology &Therapeutics, EarlyView.
The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld, Geetha S. Iyer, Suna C. Seo, Andrew Giffin, Andrew L. Simon, Sheryl A. Kluberg, Emma R. Hoffman, Jamal T. Jones, Sarah K. Dutcher, Joyce A. Korvick   +9 more
wiley   +1 more source

Commentary: Breaking tradition: should biostatistics doctoral qualifying exams evolve to better serve our students' ability to demonstrate readiness to conduct independent research?

Frontiers in Public Health
Andrew J. Spieker
doaj   +1 more source

Implementation of OMOP and ConcePTION Common Data Models in CPRD GOLD: Risk of Bleeding and Cardiovascular Outcomes From Anticoagulant Use

Clinical Pharmacology &Therapeutics, EarlyView.
The impact of the choice of common data model (CDM) approach on the study results in a real‐world evidence (RWE) study is unknown. We aimed to determine potential differences in the results of an RWE study when data were mapped to two different CDMs, ConcePTION and OMOP. With the same instance of CPRD GOLD, data were mapped to both CDMs. Using the same
Nicholas B. Hunt, Patrick Souverein, Marloes Bazelier, Nicola Barclay, Antonella Delmestri, Miriam Sturkenboom, Daniel Prieto‐Alhambra, Helga Gardarsdottir, Olaf Klungel   +8 more
wiley   +1 more source

Active Learning of Biostatistics in Medical Education: An Educational Intervention Using Algorithms, Article Analysis and SPSS Simulation. [PDF]

Cureus
Quinapanta Castro NI, Escobar C, Choez-A JF.   +2 more
europepmc   +1 more source

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study

Clinical Pharmacology &Therapeutics, EarlyView.
AGILE (NCT04746183) is a Phase Ib/IIa platform, evaluating candidates to treat COVID‐19. Candidate Specific Trial 6 evaluated the safety and optimal dose of a novel intravenous formulation of favipiravir in a dose‐escalating, open‐label, randomized, controlled, Bayesian adaptive Phase Ib trial.
Tim Rowland, Richard FitzGerald, Elizabeth Challenger, Laura Dickinson, Laura J. Else, Lauren Walker, Colin Hale, Victoria Shaw, Callum Kelly, Rebecca Lyon, Jennifer Gibney, Karim Dhamani, Margaret Irwin, Yvanne Enever, Michelle Tetlow, William Wood, Helen Reynolds, Justin Chiong, Orod Osanlou, Henry Pertinez, Katie Bullock, William Greenhalf, Andrew Owen, David G. Lalloo, Michael Jacobs, Julian A. Hiscox, Thomas Jaki, Pavel Mozgunov, Geoffrey Saunders, Gareth Griffiths, Saye H. Khoo, Thomas E. Fletcher, on behalf of the AGILE CST‐6 Study Group, Shazaad Ahmad, Christopher J. Edwards, Lesley Dry, Georgie McKenzie, Aleksandra Ros, Michael Stackpoole, Laura Bradley, Karen Jennings‐Wilding, Nicholas Paton, Fred Hayden, Janet Darbyshire, Amy Lucas, Ulrika Lorch, Andrew Freedman, Richard Knight, Steven Julious   +48 more
wiley   +1 more source

Correction: Trend change in delayed first antenatal care visit among reproductive‑aged women in ethiopia: multivariate decomposition analysis. [PDF]

Reprod Health
Gebeyehu AA, Muche AA, Woldemariam M, Yenew C, Atikilt G, Andualem M, Mebrat A.   +6 more
europepmc   +1 more source

CytoBatchFlagR: A Comprehensive Framework to Objectively Assess High‐Parameter Cytometry Data for Batch Effects

Cytometry Part A, EarlyView.
ABSTRACT Rapid advancements in mass and flow cytometry technologies have allowed researchers to generate and analyze high‐dimensional single cell datasets, often utilizing upwards of 40 protein markers. Such high‐parameter cytometry is increasingly used in longitudinal immunological studies, but technical variations across experimental batch runs can ...
Shruti Eswar, Zachary T. Koenig, Amanda R. Tursi, José Cobeña‐Reyes, Tamara Tilburgs, Sandra Andorf   +5 more
wiley   +1 more source

Author Correction: Leveraging deep single-soma RNA sequencing to explore the neural basis of human somatosensation. [PDF]

Nat Neurosci
Yu H, Nagi SS, Usoskin D, Hu Y, Kupari J, Bouchatta O, Yan H, Cranfill SL, Gautam M, Su Y, Lu Y, Wymer J, Glanz M, Albrecht P, Song H, Ming GL, Prouty S, Seykora J, Wu H, Ma M, Marshall A, Rice FL, Li M, Olausson H, Ernfors P, Luo W.   +25 more
europepmc   +1 more source